Hepatitis C, B, D, and A: contrasting features and liver function abnormalities in heroin addicts.

Over 90% of intravenous heroin addicts (IVHAs) carry the hepatitis C virus (HCV). The other hepatitis viruses, A, B, D, and G are relatively unimportant in IVHAs compared to HCV although active hepatitis B may demonstrate a chronic, degenerative course identical to that of HCV. The clinical course of HCV and active hepatitis B may span three or more decades. It is helpful to classify patients as in the active, cirrhosis, or liver failure stages. Only in the active, early stage are the liver enzymes, ALT and AST, likely to be elevated. It is this stage that will most likely respond to antiviral therapy. HCV has so many extra-hepatic manifestations including immune suppression, collagen diseases, and possibly lymphoma and leukemia that the disease is best termed HCV syndrome rather than simple hepatitis.

Cocaine abuse in methadone maintenance patients is associated with low serum methadone concentrations.

Cocaine abuse in methadone maintenance patients has emerged as a significant clinical problem. To determine if raising the daily methadone dosage is an effective way to eliminate cocaine abuse, 74 methadone maintenance patients maintained at daily dosages between 30 and 80 mg and who chronically abused cocaine were studied by a standard protocol. A total of 21 (28.4%) subjects ceased cocaine abuse when their methadone dosage was progressively raised to a maximal daily dose of 160 mg. Cocaine abuse appeared to accelerate elimination of methadone, since inadequate methadone serum concentrations (below 100 ng/ml) were found in 48 of 67 (71.6%) subjects tested 24 hours after a 100 mg oral methadone dose. Although cocaine abuse in methadone maintenance patients may respond to raising the daily methadone dosage, alternative treatments for cocaine abuse in methadone maintenance patients must be identified since cocaine abuse may lower serum methadone concentrations.

Seroprevalence of hepatitis A, B, C, and D markers and liver function abnormalities in intravenous heroin addicts.

To determine the most prevalent forms of hepatitis in intravenous heroin addicts, 389 addicts consecutively admitted to outpatient treatment clinics throughout California were tested for antibodies to hepatitis A (anti-HAV), B core (anti-HBc), B surface (anti-HBs), C (anti-HCV), D (anti-HDV), and B surface antigen (HBsAg). The majority were also tested for serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase, lactic dehydrogenase, total bilirubin, globulins, albumin, and platelet count. The seroprevalence of each marker was: anti-HAV (40.7%); anti-Hbc (73.6%); anti-HBs (46.7%); anti-HCV (93.6%); anti-HDV (9.6%), and HBsAg (3.5%). No single case was positive for IgM, anti-HAV, or for both HBsAg and anti-HDV, indicating the presence of recent hepatitis A or hepatitis D infection. Abnormal liver enzymes, serum proteins, total bilirubin, and platelet count were found to be normal in 5.3 to 44.8% of anti-HCV cases indicating persistent infection. Among anti-HCV cases, elevated total bilirubin or a low platelet count was invariably associated with one or more liver enzyme and protein abnormalities. We conclude that while acute hepatitis may be frequent and caused by various viral types, hepatitis C is the primary form of chronic hepatitis found in intravenous heroin addicts. Almost half of hepatitis C cases demonstrate liver function abnormalities indicating persistent infection that has the potential to be contagious and progress to cirrhosis, liver failure, and hepatocellular carcinoma.

Management of traumatic oral-facial injury in the hemophiliac patient with inhibitor: case report.

This report describes identification of Factor VIII inhibitor in a patient who then received immune tolerance therapy. The precipitating event was a traumatic orofacial injury that was nonresponsive to traditional factor-replacement therapies. An inhibitor complicates medical and dental management of the hemophiliac patient because it counteracts usual techniques of hemorrhage control using coagulation agents derived from Factor VIII (Monoclate--Armour, Blue Bell, PA). Successful identification and management of the inhibitor patient require communication and consultation between the physician and dentist, up-to-date knowledge regarding the hemophiliac patient's bleeding and infusion history and aggressive application of local adjunctive hemostatic therapies.

Early amniocentesis: outcome, risks, and technical problems at less than or equal to 12.8 weeks.

OBJECTIVE: It is the purpose of this report to evaluate our experience with amniocentesis at less than or equal to 12 weeks' gestation. STUDY DESIGN: Medical records of 936 patients at less than or equal to 12.8 weeks' gestation undergoing genetic amniocentesis between Oct. 1, 1986, and June 30, 1990, were evaluated for gestational age, indication, frequency of needle insertion, amniocentesis complications, and pregnancy outcome. RESULTS: There were seven miscarriages within 2 weeks of amniocentesis (0.7%), 21 miscarriages before 28 weeks (2.2%), and four stillbirths or neonatal deaths (0.4%), resulting in a total postprocedural loss rate of 3.4%. There were 26 chromosomally abnormal fetuses (2.8%). The spontaneous abortion rate in ultrasonographically normal pregnancies at less than 14 weeks, not undergoing amniocentesis, has been estimated at 2.1% to 3.2%. CONCLUSION: Amniocentesis at 12 weeks is a viable option for patients desiring earlier prenatal genetic diagnostic information.

The roles of ultrasonography and amniocentesis in evaluation of elevated maternal serum alpha-fetoprotein.

A total of 681 pregnant women were referred for evaluation of elevated maternal serum alpha-fetoprotein levels. Ultrasonographic examination yielded an explanation for the elevation of maternal serum alpha-fetoprotein in 42% of patients. Diagnoses made by ultrasonography included incorrect fetal dating, multiple gestation, fetal death, open neural tube defect, abdominal wall defect, placental abnormalities, cystic hygroma, renal anomalies, and oligohydramnios. Optimal prenatal diagnosis of fetal anomalies also requires the use of amniocentesis in many patients. Amniocentesis may be obviated if fetal dating is incorrect, if an unsuspected multiple gestation is discovered, or if there is a clear anomaly and the parents do not desire genetic counseling based on karyotype information. If the fetus appears normal, the ultrasonographic results are equivocal, or the parents desire more detailed genetic counseling when an anomaly is found by ultrasonography, then amniocentesis should be performed. Thirteen abnormalities were diagnosed by amniocentesis alone in this group.

Abnormal adrenal gland metabolism in opioid addicts: implications for clinical treatment.

Adrenal gland metabolism is markedly altered in heroin addicts. During daytime hours, the addict may suffer corticoid deficiency of the addisonian type, and in the evening, an excess of the cushingoid type. The high plasma levels of cortisol that are found in the evening in addicts antagonize endogenous opioids in a manner similar to naloxone. In the present study, 72% of the heroin addicts who sought treatment demonstrated reduced adrenal cortisol reserve. Effective immune and stress responses are dependent on adrenal cortisol reserve. This finding provides an explanation for the heroin addict's vulnerability to AIDS and other infectious diseases. One of methadone's greatest attributes is that it helps normalize adrenal metabolism. Clinical methods to at least partially correct adrenal metabolism may enhance current opioid addiction treatment modalities.

Quantitative urine levels of abusable drugs for clinical purposes.

Urine screening by polarized fluorescent immunoassay (PFI), which can quantitate concentrations of drugs of abuse within specific ranges, has recently been developed. It is rapid and inexpensive, so it can be clinically used on a routine basis. Reported here are the urine concentrations of marijuana, cocaine, phencyclidine, and amphetamine metabolites in 790 clinical patients who either sought medical detoxification for a self-diagnosis of addiction, or a counseling and urine testing program with the self-perception that they were occasional, nonaddicted users. Mean urine concentrations of cocaine, phencyclidine, and amphetamine, but not marijuana, metabolites were significantly higher in addicted than nonaddicted patients. Sequential urine tests in addicts progressively demonstrate reduced urine concentrations for as long as several weeks if cessation of usage has occurred. Nonaddicted, occasional users usually produce a negative urine sample within 2 to 3 days. Despite some overlap in urine concentrations between addicted and nonaddicted users at the time of admission for treatment, quantitative urine testing is a valuable adjunct in the clinical diagnosis and treatment of drug abuse.

Ultrasonography-guided early amniocentesis in singleton pregnancies.

Between October 1, 1986, and September 30, 1987, 1721 amniocenteses were performed at the University of California, Davis, Medical Center. Of these procedures 527 (30.6%) were early amniocenteses. Medical records were reviewed for maternal age, amniocentesis indication, color of amniotic fluid, gestational age, frequency of needle insertion, complications of amniocentesis and delivery, results of prenatal testing, and pregnancy outcome. Complete follow-up data were available for 517 (98.1%). There were 10 miscarriages before 28 weeks' gestation (1.9%), one loss after 28 weeks (0.2%), and one stillbirth (0.2%), resulting in a total postprocedural loss rate of 2.3%. Miscarriage within 2 weeks of amniocentesis occurred in four subjects (0.8%).

Quantitative urine testing. A new tool for diagnosing and treating cocaine use.

The new quantitative urine tests for cocaine are an easy and inexpensive method of diagnosing and monitoring use of this drug and thus are practical for the primary care physician's office. They may help differentiate between occasional and addicted users, thus establishing the severity of the problem for the patient and family, employer, or school officials. Although the tests cannot be used for legal applications, they have great clinical value. The receptivity of patients and third parties to urine testing has been gratifying. Physicians are encouraged to consider use of these tests in office assessment.

A prenatal diagnostic center's first-year experience with the California alpha-Fetoprotein Screening Program.

The University of California Davis Medical Center has offered secondary and tertiary care to pregnant patients with abnormal maternal serum alpha-fetoprotein levels since the start of the California alpha-Fetoprotein Screening Program in April 1986. In our first year of involvement with this method of prenatal screening, 452 patients were referred to our center for further evaluation and follow-up of either high or low maternal serum alpha-fetoprotein levels, as determined by the standard multiple of the median adjusted for maternal weight, race, and presence of insulin-dependent diabetes mellitus. This article presents the first-year results of our clinical experience. Information is presented concerning medical complications, screening and diagnostic test results and their confirmation, clinical procedures performed, and postpartum follow-up reports. Findings of pregnancy outcomes associated with low and high alpha-fetoprotein levels are presented and discussed.

Alpha-fetoprotein levels in amniotic fluid between 11 and 15 weeks.

We have shown that alpha-fetoprotein levels in amniotic fluid peak at 13 weeks and then fall by about 10% a week until 20 weeks. Use of cutoff levels obtained by extrapolation backward from medians at later dates gives results that are too high and could cause diagnostic errors. The ability to monitor alpha-fetoprotein levels accurately provides an advantage to this method of early prenatal diagnosis.